Biotech Values

[DewDiligence]

VERV phase-1b data_at AHA possibly worrisome:

https://finance.yahoo.com/news/verve-therapeutics-announces-interim-data-203000076.html

Two patients experienced serious adverse events, which were each cardiovascular events in the context of severe underlying ASCVD. One patient dosed in the 0.3 mg/kg cohort had a fatal cardiac arrest approximately five weeks after treatment due to underlying ischemic heart disease, which was determined by the investigator and independent data and safety monitoring board (DSMB) to be not related to treatment.

One patient dosed in the 0.45 mg/kg cohort experienced a myocardial infarction (Grade 3) the day after treatment. The event was considered potentially related to treatment due to the proximity to dosing.

VERV held a CC today at 6:30pm ET. (I did not listen.)